|
Tuesday, April 10, 2007
Orexigen Sets IPO Pricing Range
San Diego-based Orexigen Therapeutics, a biopharmaceutical firm developing treatments for central nervous system disorders, has set the pricing range for the company's IPO. The firm said in a filing with the SEC last night that it will offer 6,000,000 shares of its common stock between $11.00 and $13.00 per share. The company is looking to trade as OREX on the Nasdaq Global Market. The IPO is being underwritten by Merrill Lynch & Co., JPMorgan, JMP Securities, and Leerink Swann & Company. The firm is venture backed by Domain Associates, Kleiner Perkins Caufield and Byers, Montreux Equity Partners, Morgenthaler Ventures, MPM Capital, Scale Venture Partners, Sofinnova Ventures, and Wasatch Advisors.
posted on Tuesday, April 10, 2007
|
 RSS
 Email
Twitter
Previous news:
Monday, July 6, 2009
Thursday, July 2, 2009
Wednesday, July 1, 2009
Tuesday, June 30, 2009
Monday, June 29, 2009
|
